Cargando…

Correction: Comprehensive Sieve Analysis of Breakthrough HIV-1 Sequences in the RV144 Vaccine Efficacy Trial

Detalles Bibliográficos
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2016
Materias:	Correction
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4727936/ https://www.ncbi.nlm.nih.gov/pubmed/26812465 http://dx.doi.org/10.1371/journal.pcbi.1004733

Ejemplares similares

Comprehensive Sieve Analysis of Breakthrough HIV-1 Sequences in the RV144 Vaccine Efficacy Trial
por: Edlefsen, Paul T., et al.
Publicado: (2015)

Correction: RV144 HIV-1 vaccination impacts post-infection antibody responses
por: Mdluli, Thembi, et al.
Publicado: (2021)

RV144 vaccine imprinting constrained HIV-1 evolution following breakthrough infection
por: Lewitus, Eric, et al.
Publicado: (2021)

CD8 and CD4 Epitope Predictions in RV144: No Strong Evidence of a T-Cell Driven Sieve Effect in HIV-1 Breakthrough Sequences from Trial Participants
por: Dommaraju, Kalpana, et al.
Publicado: (2014)

T-cell based sieve analysis ties HLA A*02 to vaccine efficacy and IgA-C1 immune correlate in RV144 Thai trial
por: Hertz, T, et al.
Publicado: (2012)

Accuracy of Clinical Diagnosis of Dengue Episodes in the RV144 HIV Vaccine Efficacy Trial in Thailand
por: Pitisuttithum, Punnee, et al.
Publicado: (2015)

Magnitude and Breadth of the Neutralizing Antibody Response in the RV144 and Vax003 HIV-1 Vaccine Efficacy Trials
por: Montefiori, David C., et al.
Publicado: (2012)

RV144 HIV-1 vaccination impacts post-infection antibody responses
por: Mdluli, Thembi, et al.
Publicado: (2020)

Integrated systems approach defines the antiviral pathways conferring protection by the RV144 HIV vaccine
por: Fourati, Slim, et al.
Publicado: (2019)

SieveSifter: a web-based tool for visualizing the sieve analyses of HIV-1 vaccine efficacy trials
por: Fiore-Gartland, Andrew, et al.
Publicado: (2017)

Fcgbp – A Potential Viral Trap in RV144
por: Schwartz, Jacquelyn L
Publicado: (2014)

Structural analysis of the unmutated ancestor of the HIV-1 envelope V2 region antibody CH58 isolated from an RV144 vaccine efficacy trial vaccinee()
por: Nicely, Nathan I., et al.
Publicado: (2015)

The FCGR2C allele that modulated the risk of HIV-1 infection in the Thai RV144 vaccine trial is implicated in HIV-1 disease progression
por: Lassaunière, Ria, et al.
Publicado: (2018)

Extensive glycoform heterogeneity in the gp120 envelope proteins used in the RV144 trial
por: Yu, B, et al.
Publicado: (2012)

Sieve analysis of breakthrough HIV-1 sequences in HVTN 505 identifies vaccine pressure targeting the CD4 binding site of Env-gp120
por: deCamp, Allan C., et al.
Publicado: (2017)

Comparison of Antibody Responses Induced by RV144, VAX003, and VAX004 Vaccination Regimens
por: Karnasuta, Chitraporn, et al.
Publicado: (2017)

Glycan modifications to the gp120 immunogens used in the RV144 vaccine trial improve binding to broadly neutralizing antibodies
por: Doran, Rachel C., et al.
Publicado: (2018)

Molecular epidemiology of the protective RV144 V2 loop epitope
por: Cardozo, T
Publicado: (2012)

Author Correction: A comprehensive update to the Mycobacterium tuberculosis H37Rv reference genome
por: Chitale, Poonam, et al.
Publicado: (2022)

Correction to Lancet Glob Health 2021; 2: 144–60
Publicado: (2021)

Additional boosting to the RV144 vaccine regimen increased Fc-mediated effector function magnitude but not durability
por: Shubin, Zhanna, et al.
Publicado: (2023)

OA07-04 LB. Immunogenicity of ALVAC-HIV® (vCP1521) and AIDSVAX® B/E prime boose vaccination in RV144, the Thai Phase III HIV vaccine trial
por: de Souza, MS, et al.
Publicado: (2009)

Plasma IgG to Linear Epitopes in the V2 and V3 Regions of HIV-1 gp120 Correlate with a Reduced Risk of Infection in the RV144 Vaccine Efficacy Trial
por: Gottardo, Raphael, et al.
Publicado: (2013)

Characterization of HIV-1 gp120 antibody specificities induced in anogenital secretions of RV144 vaccine recipients after late boost immunizations
por: Akapirat, Siriwat, et al.
Publicado: (2018)

Correction: Identification of Rv3852 as an Agrimophol-Binding Protein in Mycobacterium tuberculosis
Publicado: (2015)

Correction: Polyethylene Oxide (PEO) and Polyethylene Glycol (PEG) Polymer Sieving Matrix for RNA Capillary Electrophoresis
por: Yamaguchi, Yoshinori, et al.
Publicado: (2015)

Importance of neutralization sieve analyses when seeking correlates of HIV-1 vaccine efficacy
por: Montefiori, David C
Publicado: (2014)

Genetic impact of vaccination on breakthrough HIV-1 sequences from the Step trial
por: Rolland, Morgane, et al.
Publicado: (2011)

Correction: Clinical outcomes of breakthrough COVID-19 after booster vaccination in patients with systemic rheumatic diseases
Publicado: (2022)

Author Correction: High permeability sub-nanometre sieve composite MoS(2) membranes
por: Sapkota, Bedanga, et al.
Publicado: (2020)

Correction: SARS-CoV-2 vaccine breakthrough infection in the older adults: a meta-analysis and systematic review
por: Jing, Xiaohui, et al.
Publicado: (2023)

FILTRATION, DIFFUSION, AND MOLECULAR SIEVING THROUGH POROUS CELLULOSE MEMBRANES
por: Renkin, Eugene M.
Publicado: (1956)

Antibodies to the envelope protein protect macaques from SIVmac251 acquisition in an immunization regimen that mimics the RV-144 Thai trial
por: Franchini, G, et al.
Publicado: (2012)

Machine Learning Methods Enable Predictive Modeling of Antibody Feature:Function Relationships in RV144 Vaccinees
por: Choi, Ickwon, et al.
Publicado: (2015)

Correction: Cystathionine-Gamma-Lyase Gene Deletion Protects Mice against Inflammation and Liver Sieve Injury following Polymicrobial Sepsis
por: Gaddam, Ravinder Reddy, et al.
Publicado: (2017)

Correction: Rv1460, a SufR homologue, is a repressor of the suf operon in Mycobacterium tuberculosis
Publicado: (2018)

Correction to: Efficacy and Safety of Sublingual Fentanyl Tablets in Breakthrough Cancer Pain Management According to Cancer Stage and Background Opioid Medication
por: Guitart, Jordi, et al.
Publicado: (2018)

Correction to: Timing of pubertal stages and breast cancer risk: the Breakthrough Generations Study
por: Bodicoat, Danielle H., et al.
Publicado: (2020)

Correction to: Risk Factors Associated With Hospitalization and Death in COVID-19 Breakthrough Infections
Publicado: (2022)

Correction: Molecular modelling and simulation studies of the Mycobacterium tuberculosis multidrug efflux pump protein Rv1258c
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_d77r4uqbdkkdc1ouvdl96vpju5